NCT00025116 2020-04-06
ZD 1839 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
Canadian Cancer Trials Group
Phase 2 Completed
Canadian Cancer Trials Group
Memorial Sloan Kettering Cancer Center
AstraZeneca
Benaroya Research Institute
AstraZeneca
AstraZeneca